Cannabis and Mental Health: Risks, Protective Factors, and Current Evidence

The relationship between cannabis and mental health is one of the most complex and controversially discussed topics in cannabis science. The evidence base is extensive but not always conclusive – correlation and causation are difficult to disentangle, individual differences are large, and the political charge of the topic complicates sober scientific examination. This article analyses the available evidence on the most important mental health topics related to cannabis.

## The Biphasic Effect of Cannabis on Anxiety

Cannabis shows a characteristic biphasic pattern regarding anxiety: low doses can be anxiolytic; high doses can trigger or worsen anxiety. This phenomenon is one of the best-documented effects of THC on the psyche and has direct relevance for safer use.

**Neurobiological Background:** THC acts as a partial agonist at the CB1 receptor. At low concentrations, THC activates CB1 receptors in brain regions associated with reward and relaxation (ventral tegmental area, nucleus accumbens), producing a pleasant, relaxing effect. At high concentrations, THC overactivates CB1 receptors in the amygdala – the brain's fear centre. The amygdala is densely populated with CB1 receptors, and excessive stimulation triggers anxiety responses: tachycardia, chest tightness, paranoia, catastrophic thinking.

**The Role of CBD:** CBD modulates THC's effects by acting as a negative allosteric modulator at the CB1 receptor – it changes the receptor's shape so that THC docks less effectively. Additionally, CBD acts through the 5-HT1A serotonin receptor as an anxiolytic. Cannabis with a balanced THC:CBD ratio (e.g., 1:1) produces anxiety reactions less frequently than high-potency, low-CBD cannabis. The increasing breeding for high THC content with simultaneous reduction of CBD in modern cannabis is a factor that has elevated anxiety risk.

**Clinical Studies:** A meta-analysis by Sharpe et al. (2020, Neuroscience & Biobehavioral Reviews) confirmed the biphasic effect: in experimental settings, low THC doses (7.5 mg oral) reduced subjective anxiety, while high doses (12.5 mg oral) increased it. Individual variability is considerable – factors such as genetics (COMT gene polymorphism), previous cannabis experience, personality traits (neuroticism), and current stress levels influence the response.

**Self-Medication for Anxiety Disorders:** Approximately 20–25% of people with anxiety disorders report using cannabis for symptom relief. Short-term this can be subjectively effective. Long-term, however, longitudinal studies (Feingold et al., 2022, Journal of Psychiatric Research) show that regular cannabis use in anxiety patients does not improve anxiety symptoms and in many cases worsens them – presumably through sensitisation of anxiety circuits and tolerance development.

## Cannabis and Depression: A Complicated Relationship

The relationship between cannabis and depression is bidirectional: depressed individuals are more likely to use cannabis (self-medication), and regular cannabis use is associated with increased depression risk. Disentangling these two directions is methodologically challenging.

**Short-Term Effects:** Cannabis can produce short-term mood improvements through activation of the dopaminergic reward system. This effect is real but temporary – and is often misinterpreted as evidence for cannabis "effectiveness" against depression.

**Long-Term Risks:** Several prospective longitudinal studies (e.g., the Christchurch Health and Development Study, New Zealand; the NESDA Study, Netherlands) show that regular cannabis use during adolescence increases the risk of depressive disorders in adulthood by 1.4 to 2-fold. Daily use further elevates the risk.

**Anhedonia – Loss of Joy:** Chronic cannabis use can desensitise the dopamine system. The result: activities that normally produce pleasure – sports, social contacts, hobbies, work – generate less satisfaction. This state is called anhedonia and is a core symptom of clinical depression. Desensitisation is reversible in most people after a multi-week abstinence period – but recovery takes time.

**Amotivational Syndrome:** Regular, high-dose cannabis use can lead to a state described as amotivational syndrome: reduced drive, indifference towards long-term goals, procrastination, and social withdrawal. Whether this is an independent cannabis effect or a manifestation of subclinical depression is debated. The clinical reality is: many regular users report this pattern.

## Psychosis and Schizophrenia Vulnerability: The Strongest Evidence

Psychosis risk is the most researched and empirically most solidly supported psychiatric risk factor of cannabis use. The evidence comes from several large, methodologically rigorous studies:

**Key Studies:** The Swedish Conscript Study (Andréasson et al., 1987; follow-up Zammit et al., 2002): 50,087 Swedish conscripts were followed for 27 years. Cannabis use at age 18 was dose-dependently associated with increased schizophrenia risk – with heavy use (> 50 times) a 6-fold increased risk. The Dunedin Multidisciplinary Health and Development Study (Caspi et al., 2005, Biological Psychiatry): this New Zealand birth cohort study showed that adolescent cannabis use increased psychosis risk – but only in persons with a specific genetic variant of the COMT gene (Val/Val allele). The EU-GEI Study (Di Forti et al., 2019, Lancet Psychiatry): a study across 11 European cities showed that daily use of high-potency cannabis (THC > 10%) increased psychosis risk 5-fold. In cities where high-potency cannabis predominated (Amsterdam, London), 20–30% of first-episode psychoses were statistically attributable to cannabis use.

**The Vulnerability-Stress Model:** Cannabis does not cause psychosis in a simple causal chain – it interacts with pre-existing vulnerabilities. The most important vulnerability factors are: genetic predisposition (family history of psychosis, specific gene variants), early onset age (before 15 is particularly high risk), high THC doses and daily use, concurrent psychosocial stressors (trauma, neglect, migration). In this model, cannabis is not the sole cause but a potent risk catalyst.

**Schizophrenia Vulnerability in Detail:** People with a first-degree relative with schizophrenia already have a lifetime risk of approximately 10% (vs. 1% in the general population). Cannabis use in these individuals can further elevate this risk and advance illness onset by an average of 2–3 years. The prodromal phase (early symptoms before the full illness picture) can be accelerated by cannabis. Warning signs in the prodromal phase: social withdrawal, unusual thoughts, increased suspiciousness, perceptual disturbances.

## PTSD Treatment: Between Hope and Evidence Gaps

Post-traumatic stress disorder (PTSD) is one of the areas where cannabis is attributed the greatest therapeutic potential – but the evidence is complex here too.

**Why Cannabis Might Help with PTSD:** The endocannabinoid system is centrally involved in extinction (unlearning) of fear memory. In PTSD patients, this mechanism does not function properly – traumatic memories are not successfully recoded as "no longer threatening." Endocannabinoids (particularly anandamide) are necessary for this extinction process. THC could theoretically support this process. Additionally, cannabis can reduce PTSD-typical symptoms such as nightmares, hyperarousal, and sleep disturbances. Nabilone, a synthetic THC derivative, significantly reduced nightmares in PTSD patients in small studies.

**What the Evidence Shows:** Several observational studies and a growing number of controlled trials (e.g., Bonn-Miller et al., 2021) show short-term symptom improvements in PTSD patients using cannabis. However: study quality is predominantly low to moderate (small samples, short durations, missing control groups). Long-term studies are almost entirely absent. There is a substantial risk of self-medication and dependency in this patient group. The German Medical Association and AWMF guidelines classify cannabis for PTSD as an experimental therapy option – not a first-line treatment.

**Differentiated View:** CBD (without THC) shows promising anxiolytic and anti-traumatic effects in preclinical studies with a low side effect profile. THC alone carries the risk of intensifying hypervigilance in PTSD patients. A combination of THC and CBD under medical supervision appears most promising.

## Sleep Disorders: Quick Help, Long-Term Trap

Cannabis – particularly THC – is one of the most commonly used substances for self-medication of sleep disorders. An estimated 30–50% of regular cannabis users consume partly due to sleep problems.

**Short-Term Sleep Effects:** THC shortens sleep onset latency (time to fall asleep). THC extends deep sleep (slow-wave sleep) in the first weeks of use. THC reduces REM sleep (the phase during which dreaming occurs). Subjective sleep quality is often perceived as improved.

**Long-Term Problems:** With regular use, tolerance to sleep-promoting effects develops quickly – after 2–4 weeks, the effect is often significantly reduced, encouraging dose escalation. REM sleep reduction has consequences: REM sleep is important for emotional processing, memory consolidation, and creative thinking. Chronic REM suppression can contribute to emotional dysregulation. Upon cessation after regular use, REM rebound occurs: the REM phase becomes excessively long and intense, leading to vivid, often unpleasant dreams. This rebound effect is one of the most uncomfortable aspects of cannabis withdrawal and can persist for weeks.

**CBN and CBD:** CBN (cannabinol), a degradation product of THC, is traditionally described as sedating. However, the scientific evidence for CBN's sleep-promoting effect is surprisingly thin – a study by Corroon (2021) found no convincing evidence for an independent sedative effect. CBD shows possibly slightly sleep-promoting effects at higher doses (> 160 mg), but the evidence is preliminary. The sleep-promoting effect of cannabis appears to be primarily a THC effect.

## Cannabis Use Disorder (CUD)

Cannabis use disorder is a formally recognised psychiatric diagnosis (DSM-5, ICD-11) and represents the most significant long-term risk of regular cannabis use.

**Epidemiology:** Approximately 9% of all people who have ever used cannabis develop CUD. Among regular users, this proportion rises to 17–33%. Among daily users, risk is 25–50%. With onset before age 18, risk is 4–7 times higher than with later onset.

**Diagnostic Criteria (DSM-5):** At least 2 of the following 11 criteria within 12 months: use in larger amounts or over longer periods than intended; persistent desire or unsuccessful attempts to control use; significant time spent obtaining, using, and recovering; craving; failure to fulfil obligations (work, school, family); continued use despite social problems; giving up activities in favour of use; use in hazardous situations; continued use despite physical or psychological problems; tolerance development; withdrawal symptoms.

**Withdrawal Symptoms:** Cannabis withdrawal syndrome has been officially recognised in DSM-5 since 2013. Symptoms begin 24–72 hours after last use and can persist 1–3 weeks: irritability and aggression, sleep disturbances and vivid dreams, reduced appetite and weight loss, restlessness and anxiety, depressed mood, sweating and chills, headaches. Symptoms are milder than opioid or alcohol withdrawal but can be significantly distressing and are the most common reason for relapse.

**Treatment Options:** Psychotherapy (particularly cognitive behavioural therapy – CBT – and Motivational Enhancement Therapy – MET) is the evidence-based first-line treatment. There are no approved medications for CUD, but N-acetylcysteine (NAC) and gabapentin show promising results in studies. Outpatient addiction counselling is widely available and free throughout Germany.

## Risk Factors: Who Is Particularly Vulnerable?

Not all cannabis users carry the same risk for mental health harm. Research has identified clear risk factors:

**Age:** Onset before age 15 is associated with the highest risk for all mental health effects – psychosis, depression, dependency, cognitive impairment. The brain develops until approximately age 25, and adolescence is a particularly vulnerable phase. Each additional year that onset is delayed reduces risk.

**Genetics:** Certain gene variants significantly influence individual response to cannabis. The COMT gene (Val158Met polymorphism) affects dopamine degradation in the prefrontal cortex – the Val/Val variant is associated with increased psychosis risk under cannabis influence. The AKT1 gene influences signal transduction after CB1 activation – certain variants increase psychosis risk. Polygenic risk scores for schizophrenia correlate with the likelihood of developing psychotic symptoms under cannabis.

**Dose and Frequency:** Risk increases with the amount consumed and frequency of use. Daily use of high-potency cannabis (> 15% THC) represents the highest risk profile. Occasional use (1–2 times per month) of moderate THC cannabis is associated with significantly lower risks.

**THC:CBD Ratio:** High-potency, low-CBD cannabis is riskier than cannabis with a balanced THC:CBD profile. CBD has neuroprotective and anxiolytic effects and can partially buffer THC's psychotogenic effects.

**Psychiatric History:** Any pre-existing psychiatric condition – particularly anxiety disorders, depression, bipolar disorder, and personality disorders – increases the risk of adverse cannabis effects. Family history of psychosis or schizophrenia is the strongest individual risk factor.

## Protective Factors: What Reduces Risk

Beyond knowing risk factors, identifying protective factors is essential for harm reduction:

**Informed, Conscious Use:** Knowledge of risks and safer use practices reduces the likelihood of problematic consumption patterns. Harm reduction education is the strongest modifiable protective factor.

**Cannabis with Balanced THC:CBD Profile:** Choosing cannabis with moderate THC content and relevant CBD proportion reduces anxiety and psychosis risk. Cannabis Social Clubs can actively contribute to this protective factor through strain selection and product information.

**Moderate, Non-Daily Use:** Those who consume only occasionally (weekend use, 1–4 times per month) and maintain regular consumption breaks have a drastically lower risk profile than daily users.

**Adult-Onset Use:** Delaying use onset beyond age 21 substantially reduces risk for virtually all mental health effects.

**Stable Social Environment:** Social support, stable relationships, and meaningful occupation are protective factors against problematic consumption development.

**Professional Support for Risk Groups:** People with pre-existing mental health conditions who nevertheless consume benefit from psychotherapeutic accompaniment to monitor consumption patterns and recognise early warning signs.

## Current State of Evidence: What We Know and What We Don't

**What Science Establishes with High Confidence:** Regular cannabis use increases psychosis risk dose-dependently. Early onset (< 18 years) is associated with worse mental health outcomes. High-potency THC without CBD counterbalance is riskier. Genetic factors substantially modulate individual risk. Cannabis produces a clinically relevant dependency syndrome in a minority of users.

**What Is Controversially Discussed:** Whether cannabis plays an independent causal role in depression (confounding through self-medication). Whether amotivational syndrome is an independent cannabis effect. Whether CBD alone is therapeutically effective for anxiety disorders and PTSD. Long-term cognitive recovery after cessation in adults (studies show substantial recovery after 72 hours to 4 weeks of abstinence – but individual differences are large).

**What We Don't Yet Know:** Long-term effects of high-potency cannabis on brain development (the current high-potency generation is the first for which long-term data are still pending). Whether specific terpenes or minor cannabinoids modulate mental health risks (entourage effect on mental health). Optimal THC:CBD ratios for various therapeutic applications. The precise role of the endocannabinoid system in psychiatric disorders.

Research is advancing rapidly. Many studies from countries with legalised cannabis (Canada, USA, Uruguay) will provide important new data in coming years. Until then, the most sensible approach remains: consume informed, know your risk factors, strengthen protective factors, and seek professional help when in doubt.